ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
ORAMED PHARMACEUTICALS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$4.06−0.01 (-0.25%)
Close on Oct 19, 2026
- Market cap
- $172.56M
- P/E (TTM)
- 1.0
- Dividend yield
- 6.16%
Share price
+$1.83 (+82.06%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
ORAMED PHARMACEUTICALS INC. reported revenue of $2.00M for fiscal 2025. Free cash flow was -$5.22M.
Revenue
$2.00M
FY2025
Operating income
-$14.52M
TTM Q2 2026
Free cash flow
-$5.22M
TTM Q2 2026
EPS, diluted
$4.13
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $172.56M
- P/E ratio
- 1.0
- Price to sales
- 86.28
- Price to book
- –
- Dividend yield
- 6.16%
- Free cash flow yield
- -3.02%
Fundamentals
- Revenue
- $2.00M
- Net income
- $174.87M
- EPS, diluted
- $4.13
- Free cash flow
- -$5.22M
- Diluted shares
- 43M
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$14.52M
Net income
$174.87M
EPS, diluted
$4.13
Free cash flow
-$5.22M
Reported periodTrailing twelve months